References
- American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society, 2012
- Garcia M, Jemal A, Ward E, et al. Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society, 2007
- Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
- Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 2010;14:749-59
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
- Goldstein D, El Maraghi RH, Hammel P, et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas (oral presentation at 2014 Gastrointestinal Cancers Symposium). J Clin Oncol 2014;32(3 Suppl):abstract 178
- Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 1989;7:36-44
- Revicki DA, Feeny D, Hunt TL, et al. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 2006;15:411-23
- Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment. Sem Radiat Oncol 2003;13:176-81
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81
- Cole BF, Gelber RD, Goldhirsch A. Cox regression models for quality adjusted survival analysis. Stat Med 1993;12:975-87
- Caudill-Slosberg MA, Schwartz LM, et al. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004;109:514-19
- Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-9
- Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
- Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84-98
- Glasziou P, Simes R, Gelber R. Quality adjusted survival analysis. Stat Med 1990;9:1259-76
- Zee B, Cole B, Li T, et al. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol 1998;16:2834-9
- Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life–adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using Intergroup clinical trial data. J Clin Oncol 2002;20:1311-18
- Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 2012;43:205-17
- Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90
- Swinburn P, Lloyd A, Nathan P, et al. Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin 2010;26:1091-6
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
- Labianca R, Merelli B, Mosconi S. Treatment of advanced pancreatic cancer. Ann Oncol 2012;23(Suppl 10):x139-x140
- Chao Y, Wu C-Y, Wang JP, et al. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemother Pharmacol 2013;72:637-42
- Fairclough DL. Design and analysis of quality of life studies in clinical trials. 2nd edn. Boca Raton, FL: Chapman and Hall/CRC Press, 2010
- Irish W, Sherrill B, Cole B, et al. Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 2005;16:1458-62